RxDoctor Payments Data

Adam Rudasill, PA

Physician Assistant · Middleburg, PANPI 1720757149

Payments from drug & device makers

$6,452in general payments, 2019–2025

Across 367 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • AstraZeneca$617
  • Amgen$540
  • Lilly USA, LLC$420
  • GSK$311
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$6,452100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,452 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$6,968
Medicare patients
47
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$52,114
MounjaroTirzepatide17$33,769
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$24,886
EliquisApixaban19$24,173
OzempicSemaglutide23$21,705
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$18,771
XareltoRivaroxaban22$14,799
FarxigaDapagliflozin Propanediol19$10,975
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,865
Albuterol Sulfate HfaAlbuterol Sulfate66$2,649
Venlafaxine Hcl ErVenlafaxine Hcl22$2,482
Atorvastatin Calcium121$1,709
Aripiprazole32$1,355
Metoprolol Succinate71$1,261
Omeprazole88$1,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$111$52,11453 claims
Lilly USA, LLCMounjaro$420$33,76917 claims
AstraZenecaBreztri Aerosphere, Farxiga$617$29,74641 claims
GSKTrelegy Ellipta$311$24,88630 claims
PfizerEliquis$170$24,17319 claims
Novo NordiskOzempic$1,294$21,70523 claims
Johnson & JohnsonXarelto$181$14,79922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Middleburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →